Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Large scale innovative pro-poor programs focused on reducing maternal mortality in India: a proposal for impact evaluation (MATIND)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Sweden,United Kingdom,China,India
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-04-01
End date: 2015-09-30
Duration (months): 54.0
Total project cost (EUR): 3905283.2
EU funding (EUR): 2969172.0
Participants: 5
Project status: CLOSED

This application proposes the evaluation of two innovative large scale programs, which were set up to decrease maternal mortality among women living below the poverty line in India. India contributes 20% of global maternal deaths and has 26% of her population living below poverty line, and continues to have one of the highest maternal mortality ratios in the world. Progress with MDG 5 in India (slow thus far) is a prerequisite to achieving the goal by 2015. Both Indian programs were started to reduce maternal deaths by promoting institutional delivery and reducing access barriers to maternal healthcare for poor women. The two large scale, state run programs operate in two large Indian provinces. Each of these programs operates through the use of different innovative demand side financing mechanisms, which are specifically aimed at improving access for vulnerable groups. One program is a conditional cash transfer paid retrospectively to the woman on delivering in an institution while the other is a targeted bursary paid prospectively to accredited healthcare providers for delivery of the woman living below poverty. All payments are made by the state. While both programs are based on similar concepts, i.e. financial incentives for the provision and utilization of care; and the participation of the private sector – there are major differences in the socioeconomic contexts in which each program operates, financing mechanisms, provider payment models and incentives, quantum of financial assistance, level of private sector involvement, all of which will have a bearing on desired maternal health outcomes. China is a proposed partner on this application, as it is able to contribute important lessons regarding rural maternal health financing programs that were studied there in FP6. No such large scale demand side financing programs for maternal health have been evaluated before. The field is fairly new and recent scientific literature has recommended robust evaluations

Keywords: maternal mortality india china innovative demand side financing program evaluation
European Grid Initiative: Integrated Sustainable Pan-European Infrastructure for Researchers in Europe (EGI-INSPIRE)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Netherlands,Albania,Armenia,Bulgaria,Belarus,Switzerland,Cyprus,Czechia,Germany,Bosnia and Herzegovina,Spain,Finland,France,Georgia,Greece,Croatia,Hungary,Ireland,Israel,Italy,Lithuania,Moldova, Republic of,Montenegro,North Macedonia,Norway,Poland,Portugal,Serbia,Slovenia,Slovakia,Türkiye,United Kingdom,Switzerland,Denmark,Germany,Sweden,Latvia,Taiwan, Province of China,Philippines,Indonesia,Japan,Korea, Republic of,Australia,Singapore,Malaysia,Thailand,Romania,Netherlands,Sweden,Russian Federation,Netherlands
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-05-01
End date: 2014-12-31
Duration (months): 56.0
Total project cost (EUR): 70337893.0
EU funding (EUR): 25000000.0
Participants: 56
Project status: CLOSED

Scientific research is no longer conducted within national boundaries and is becoming increasing dependent on the large-scale analysis of data, generated from instruments or computer simulations housed in trans-national facilities, by using e Infrastructure (distributed computing and storage resources linked by high-performance networks). The 48 month EGI-InSPIRE project will continue the transition to a sustainable pan-European e-Infrastructure started in EGEE-III. It will sustain support for Grids of high-performance and high-throughput computing resources, while seeking to integrate new Distributed Computing Infrastructures (DCIs), i.e. Clouds, SuperComputing, Desktop Grids, etc., as they are required by the European user community. It will establish a central coordinating organisation, EGI.eu, and support the staff throughout Europe necessary to integrate and interoperate individual national grid infrastructures. EGI.eu will provide a coordinating hub for European DCIs, working to bring existing technologies into a single integrated persistent production infrastructure for researchers within the European Research Area. EGI-InSPIRE will collect requirements and provide user-support for the current and new (e.g. ESFRI) users. Support will also be given for the current heavy users as they move their critical services and tools from a central support model to ones driven by their own individual communities. The project will define, verify and integrate within the Unified Middleware Distribution, the middleware from external providers needed to access the e-Infrastructure. The operational tools will be extended by the project to support a national operational deployment model, include new DCI technologies in the production infrastructure and the associated accounting information to help define EGIâ€™s future revenue model.

Keywords: e infrastructure,grid,europe,supporting researchers,htc,hpc
Manipulation of senescence pathways for cancer therapy: from experimental models to clinic (PICS THERAPY)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Diagnostic tools, therapies and public health
Countries involved: Switzerland
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2011-04-01
End date: 2016-03-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: CLOSED

This proposal aims to harness a novel type of senescence that we have identified in response to acute Pten inactivation, and which we believe offers a radical therapeutic approach to target the quiescent cancer stem cell in vivo. In characterizing Pten loss Induced Cellular Senescence, which we have named PICS for short, we have discovered that PICS is distinct from other forms of cellular senescence including oncogene-induced senescence (OIS) and replicative senescence. These distinct differences are characterized by a lack of DNA damage and hyper-replication, breaking the current dogma for senescence induction. The ability to induce senescence, an irreversible growth arrest, in cells by targeting Pten signaling, without a requirement for hyper-replication and DNA damage opens up the possibility to target quiescent cells, including stem cells, that have a low proliferative index. This approach has tremendous therapeutic potential and represents one of the most exciting developments for the advancement of prostate cancer therapy in recent years. Through the manipulation of senescence induction pathways we will identify PICS enhancing drugs and redefine the paradigm for cancer therapy. By developing novel mouse models that target prostate stem cells we will evaluate these PICS pro-senescence drugs in a pre-clinical setting. Finally, these results will be cross referenced with data from human prostate stem cells and we will lay the ground work to translate this to the clinical setting, further developing the clinical potential of these findings to eradicate prostate cancer.

Keywords: pten,senescence,therapy,small molecules screening
Open Collaborative Model for Tuberculosis Lead Optimisation (ORCHID)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,United Kingdom,Slovenia,France,United States,Sweden,Switzerland,Russian Federation,Korea, Republic of,South Africa,Germany
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2015-06-30
Duration (months): 54.0
Total project cost (EUR): 8473739.9
EU funding (EUR): 5357429.0
Participants: 14
Project status: CLOSED

Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed and optimised into candidates for pre-clinical development through the Drug Development progression cascade. Three compound families are of particular interest: 1) InhA Inhibitors, 2) New potent whole cell anti-tubercular compounds with unknown mode of action and 3) new Beta-lactam/Beta-lactamase combinations for TB. A preclinical package is already in place for some of them, but further work is necessary for others in order to justify the progression of a single anti-tubercular family to the more resource intensive stages of preclinical and clinical development. The project will encompass the parallel progression of the three compound families through: A) Lead Optimization Chemistry efforts and MoA studies (Genetic and Proteomic) for whole cell inhibitors, B) In vitro and in vivo evaluation of a new orally bioavailable Beta-lactam alone or in combination with a Beta-lactamase inhibitor to evaluate the sterilising potential of the new drug/s and C) the optimization of an InhA inhibitor for later preclinical development. These efforts will yield candidate molecules for new "information rich" in vitro assays of antimycobacterial activity (artificial granuloma, activity against slow/non growing cells and activity against clinical isolates) as well as for in vivo safety and efficacy evaluation in different animal models of infection (acute and/or chronic). At this stage a single compound family will be prioritized. Further studies will be performed assessing the potential for shortening treatment in stand alone therapy as well as in combination regimens both in vitro and in vivo. Finally a Clinical Development plan will be put in place for the selected candidate molecule.

Keywords: tuberculosis,lead optimisation,drug development,drug discovery.
Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Germany,France,Italy,Spain,Austria
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-03-01
End date: 2017-12-31
Duration (months): 82.0
Total project cost (EUR): 6584623.18
EU funding (EUR): 4961654.0
Participants: 10
Project status: CLOSED

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector”, which was developed during the THERAPEUSKIN project (FP6) to treat RDEB patients by ex vivo gene therapy. This approach uses autologous skin grafts made of primary keratinocytes and fibroblasts genetically corrected with a safe (SIN) retroviral vector expressing type VII collagen under the control of the EF1alpha promoter. We have demonstrated the feasibility of the approach in pre-clinical studies in mice and the absence of tumorigenicity. We now aim at preparing and undertaking a first clinical trial in 3 selected RDEB patients. This project will involve the transfer and the adaptation from the research laboratory to clinic, of the entire experimental procedure for genetic correction of RDEB skin equivalents suitable for transplantation in patients. This will include validation of the viral pilot batches and the GMP viral vector lot, the establishment of SOPs, the identification and selection of the best GMP culture system and the scale-up of the graft preparation. A clinical-grade cell bank of primary keratinocytes and fibroblasts will be established from 3 selected RDEB patients who are tolerant towards type VII collagen. Determination of transgene integrity, analysis of the proliferative capacities of transduced keratinocytes and the level of type VII collagen expression will be assessed. Safety assessment will include tumorigenicity assays, survey of grafted genetically corrected skin and integration site analysis. The regulatory and safety issues of these procedures related to the preparation of clinical grade genetically modified cells suitable for human transplantation will be addressed. Authorization of the clinical trial by the AFSSAPS will allow the first patients to be treated and followed up. This “bench to bedside” project will serve as a proof of principle of safe gene therapy for RDEB. It has the potential to bring clinical improvement to these young patients and to represent a significant progress in the treatment of this devastating skin disease.

Keywords: recessive dystrophic epidermolysis bullosa,ex vivo gene therapy,type vii collagen,sin retroviral vector,skin equivalent transplantation
The MEtabolic Road to DIAstolic Heart Failure (MEDIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Germany,Germany,Portugal,Belgium,France,Netherlands,Spain,Norway,Hungary,Italy,United Kingdom,Italy,Italy,Ireland,Germany,Israel
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2016-06-30
Duration (months): 66.0
Total project cost (EUR): 15957343.03
EU funding (EUR): 11971721.0
Participants: 22
Project status: CLOSED

More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements contribute to DHF; 2) how diagnostic algorithms for DHF can be improved by assessing metabolic risk; 3) how correction of metabolic risk can open new therapeutic perspectives for DHF.Hereto MEDIA will: 1) Expose animal models of DHF to intense metabolic risk in order to accelerate DHF development. 2) Perform mechanistic studies in cardiomyocytes derived from DHF animal models or from DHF patients. Because of the acquired nature of metabolic risk, these studies will focus on posttranslational modifications of proteins and on epigenetic control of hypertrophy development. Their relevance for global LV function will also be appraised; 3) Perform mechanistic studies on myocardial collagen synthesis, which is enhanced by metabolic risk, and execute a phase II trial in DHF with cardiac specific antifibrotic therapy; 4) Explore the use of biomarkers as premorbid identifiers of DHF in existing cohorts of patients exposed to metabolic risk; 5) Prospectively test biomarkers and arterial stiffening, which is accelerated by metabolic risk, for their diagnostic potential in a large DHF cohort; 6) Assess myocardial metabolic substrate preference with modern imaging techniques and improve diastolic LV dysfunction through modified substrate utilization in a phase II trial. Expected results of MEDIA are: 1) Identification of metabolic risk-related mechanisms as therapeutic targets; 2) Improved diagnostic algorithms through inclusion of biomarkers and arterial stiffness tests. 3) Novel treatments consisting of modified myocardial substrate utilization and myocardial antifibrotic therapy.

Keywords: heart failure,diastole,myocardium,fibrosis,cardiomyocytes,diabetes,obesity,risk factors,therapy,diagnosis
Suicidality: Treatment Occurring in Paediatrics (STOP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Netherlands,Germany,Germany,United Kingdom,France,Spain,Spain,Italy,Germany,Canada,France,United Kingdom
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-11-01
End date: 2015-04-30
Duration (months): 54.0
Total project cost (EUR): 3748810.72
EU funding (EUR): 3000000.0
Participants: 19
Project status: CLOSED

The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Related Suicidality (PRS) in terms of phenomenology, clinical expression and time course, and may vary between children and adults. Unlike PRS, the time-course of MRS may be associated with possible differences in drug pharmacokinetics; abrupt onset; absence of suicidality prior to start of medication; and emergence of suicidality related co-morbidities after treatment. This proposal will focus on developing a web-based comprehensive methodology for the assessment and monitoring of suicidality and its mediators in children and adolescents using the HealthTrackerTM (a paediatric web-based health outcome monitoring system), with the aim of developing a Suicidality Assessment and Monitoring Module, a Bio-psycho-social Mediators of Suicidality Assessment Module, and a Suicidality-Related Psychiatric and Physical Illness Module. The information obtained will be used to computer-generate classification of suicidality using the Classification of Suicide-Related Thoughts and Behaviour (Silverman et al, 2007) and the Columbia Classification Algorithm of Suicidal Assessment (C-CASA) (Posner et al, 2007). The existing Medication Characteristics Module will be expanded to allow documentation of pharmacological characteristics of medication, to explore whether they mediate MRS. The methodology will then be tested in 3 paediatric observational trials (risperidone in conduct disorder; fluoxetine in depression, and montelukast in bronchial asthma) and standardized, which can be used pharmacovigilance and in epidemiological, observational, and registration trials.

Keywords: suicidality,healthtrackertm,medication-related suicidality,risperidone,fluoxetine,montelukast,paediatric.
West Nile Integrated Shield Project: Epidemiology, Diagnosis and Prevention of West Nile Virus in Europe (WINGS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Netherlands,Italy,Switzerland,Belgium,United States,Sweden,Hungary
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-02-01
End date: 2014-02-28
Duration (months): 37.0
Total project cost (EUR): 3922214.75
EU funding (EUR): 2938497.0
Participants: 9
Project status: CLOSED

The world is facing a variety of viral infections of high pathogenic potential. These are either novel or formerly only endemic in specific areas of the world. It is intrinsic to such emerging diseases that actions to prevent and fight them must be taken while the number of infections is still relatively low and geographically restricted. Therefore, research efforts are required well before large outbreaks occur. In addition, effective surveillance networks for a given emerging disease must be established in time. Only with tools for treatment and control (such as vaccines) it will be possible to avoid major uncontrolled outbreaks. This proposal aims at the development of these tools for the control and prevention of one of the most threatening vector-borne emerging diseases, West Nile Fever, caused by West Nile Virus (WNV), which has recently spread through North America. Although the viral strains are similar in America and Europe, different conditions for a WNV epidemic have to be taken into account, like insect vectors, reservoir hosts (birds) and their endemic virus populations plus specialities of European climate and geography. To achieve the goals of the call and to make a significant impact in the enhancement of Europe´s preparedness to WNV, the consortium has defined three major scientific and technical objectives. Firstly, to develop a diagnostic system for WNV-infections, which has no cross-reaction with other common flavivirus infections. Secondly, to develop a vaccine for humans and last but not least to establish a scientific network to collect, investigate and standardize biological data associated with WNV records using standardized methods. Several European Institutes supported by US scientist experienced with the North American outbreak will be collaborating to fight the disease from a European perspective.

Keywords: west nile virus,vaccine,diagnosis,epidemiology,surveillance,emerging disease
Socially inclusive health care financing in West Africa and India Short title: Financing health care for inclusion (HEALTH INC.)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,India,Ghana,Senegal
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-05-01
End date: 2014-10-31
Duration (months): 42.0
Total project cost (EUR): 3446246.89
EU funding (EUR): 2764046.33
Participants: 6
Project status: CLOSED

Recent health financing reforms in low and middle income countries aim to introduce affordable prepayment and subsidies for low socio-economic groups. However, while such reforms have led to increased utilization of care, often the poor and informal sector continue to be excluded from coverage. Health Inc. puts forward the hypothesis that social exclusion is an important cause of the limited success of recent health financing reforms. First, social exclusion can explain barriers to accessing health care due to disrespectful, discriminatory or culturally inappropriate practices of medical professionals and their organisations, within the context of poor accessibility and quality of care. As a consequence, removing financial barriers does not necessarily guarantee equitable access to care. Second, social exclusion can explain barriers to accessing the health financing mechanism itself. Differential access to information, bureaucratic processes, complex eligibility rules and/or crude and stigmatizing criteria for means testing prevent socially excluded groups from enrolling in financing schemes, even if they are fully subsidised. Social inclusion, by contrast, may explain why more powerful, wealthy and vocal groups disproportionately ‘capture’ the benefits of publicly funded health care. In four countries/states (Ghana, Karnataka, Maharashtra and Senegal), Health Inc. employs mixed methods to analyse whether different types of financing arrangements overcome social exclusion and also increase social inclusion by empowering socially marginalised groups. A multi-sectoral stakeholder analysis will also explore whether vulnerable populations participate in policy making and whether their needs are understood. Health Inc. will compare policies across contexts in order to elicit lessons. Local policy makers and population groups will then be consulted in a feasibility analysis to identify and test policy recommendations, which will be widely disseminated.

Keywords: financing models - accessible health care - social inclusion - social exclusion - barriers to access - financial barriers - financial coverage -vulnerable populations - low and middle income countries